Abstract
Chemotherapy at present remains the main form of treatment for cancer, though there is no clinically available antineoplastic drug that acts selectively on the tumor mass. For this reason, the scientific research is focused towards the development of novel cancer therapies and drug delivery strategies, like drug targeting, that would enhance the therapeutic efficacy of drugs while reducing their side toxicity. This review describes tree types of nanoparticles used in active targeting for cancer treatment: liposomes, lipid and polymer nanoparticles, and micelles. The opportunities and challenges achieved by the proposed strategies of active targeting have been highlighted, as well as the necessity to conciliate the targeting efficiency of drug nanocarriers with their longevity in the bloodstream.
Keywords: Cancer, drug targeting, controlled drug delivery, liposomes, solid lipid nanoparticles, SLN, nanoparticles, micelles, lipid nanocapsules (LNC)
Current Drug Delivery
Title:Active Targeting Strategies for Anticancer Drug Nanocarriers
Volume: 9 Issue: 3
Author(s): Livia Basile, Rosario Pignatello and Catherine Passirani
Affiliation:
Keywords: Cancer, drug targeting, controlled drug delivery, liposomes, solid lipid nanoparticles, SLN, nanoparticles, micelles, lipid nanocapsules (LNC)
Abstract: Chemotherapy at present remains the main form of treatment for cancer, though there is no clinically available antineoplastic drug that acts selectively on the tumor mass. For this reason, the scientific research is focused towards the development of novel cancer therapies and drug delivery strategies, like drug targeting, that would enhance the therapeutic efficacy of drugs while reducing their side toxicity. This review describes tree types of nanoparticles used in active targeting for cancer treatment: liposomes, lipid and polymer nanoparticles, and micelles. The opportunities and challenges achieved by the proposed strategies of active targeting have been highlighted, as well as the necessity to conciliate the targeting efficiency of drug nanocarriers with their longevity in the bloodstream.
Export Options
About this article
Cite this article as:
Basile Livia, Pignatello Rosario and Passirani Catherine, Active Targeting Strategies for Anticancer Drug Nanocarriers, Current Drug Delivery 2012; 9 (3) . https://dx.doi.org/10.2174/156720112800389089
DOI https://dx.doi.org/10.2174/156720112800389089 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening The Potential Therapeutic Value of Renin-Angiotensin System Inhibitors in the Treatment of Colorectal Cancer
Current Pharmaceutical Design Altered Expression of microRNAs in Serum Extracellular Vesicles in Rats with Severe Burns during Shock Stage
Current Molecular Medicine Gene and Cancer Therapy - Pseudorabies Virus: A Novel Research and Therapeutic Tool?
Current Gene Therapy Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews PET Tracers Based on 86Y
Current Radiopharmaceuticals Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Signaling Pathways Involved in Neuron-Astrocyte Adhesion and Migration
Current Molecular Medicine Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup>Lu and Conjugated to Peptides
Current Radiopharmaceuticals Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs
Current Cancer Therapy Reviews New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Editorial
Recent Patents on Inflammation & Allergy Drug Discovery Stimuli-responsive Drug Delivery Nanosystems: From Bench to Clinic
Current Nanomedicine Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective
Current Medicinal Chemistry Metabolic Fate of Endocannabinoids
Current Neuropharmacology